New diabetes drug tested in patients with liver issues
NCT ID NCT05427682
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial looked at how a single 50mg dose of pyroglutamate rongliflozin capsules behaves in 32 adults with mild or moderate liver damage and type 2 diabetes, compared to healthy volunteers. Researchers measured drug levels in the blood and tracked side effects to understand safety and dosing. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pyroglutamate rongliflozin capsules
- What this could lead to
- If successful, this study could help determine safe dosing of rongliflozin for people with liver problems and type 2 diabetes.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants, so results may not apply broadly. The drug's safety and effectiveness are still uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?
- Could a Dairy-Rich diet tame type 2 diabetes?
- Can a traditional herbal remedy tame type 2 diabetes?